AZ's Alexion extends gMG options with two Klygefa approvals
AstraZeneca's rare disease unit Alexion has won regulatory approval in the US and EU for Klygefa as a generalised myasthenia gravis (gMG) therapy, breaking new ground in the complement C5 inhibitor category.
Klygefa (gefurulimab) is a dual-binding nanobody C5 inhibitor – dosed by subcutaneous injection – that extends Alexion's presence in the C5 inhibitor class with intravenously administered products Soliris (eculizumab) and Ultomiris (ravulizumab).
The new drug – which has also been approved in Japan – is seen as an important addition to Alexion's $6.5 billion C5 inhibitor franchise as it can be administered as a subcutaneous injection once a week by gMG patients themselves using an autoinjector or prefilled syringe, freeing them from the need to make regular trips to infusion clinics.
AZ has predicted peak sales of between $1 billion and $3 billion for Klygefa, although some analysts are less optimistic as gMG, a rare autoimmune disorder characterised by reduced muscle function and severe muscle weakness, has become a crowded market.
There are already weekly subcutaneous treatment options for gMG patients in the EU and US – namely Argenx's Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase) and UCB's Rystiggo (rozanolixizumab) – but these have a different mechanism of action (both FcRn blockers) and need to be administered by a physician. In the injectable C5 inhibitor category, it will compete with UCB's once-daily, self-administered Zilbrysq (zilucoplan) shot.
Klygefa is important to AZ/Alexion as Soliris has already started to lose patent protection, with sales shrinking by a quarter to around $1 billion in the first nine months of the year due to biosimilar competition, having been a $4 billion-a-year brand at its peak.
Longer-acting Ultomiris – which requires infusions every eight weeks rather than every two – remains in the growth phase, up 16% to $4 billion in the same period, with patent protection extending to the mid-2030s.
Adding in Klygefa will allow physicians and patients to select the drug that suits them best, based on their own lifestyle and preferences, and offset further Soliris revenue declines.
"Because no two patients experience gMG in the same way, expanding the range of options available is fundamental to how we improve lives," said Samantha Masterson, president and chief executive of the Myasthenia Gravis Foundation of America (MGFA).
"The MGFA welcomes this approval and the new possibilities it opens for those who have been seeking more independence and greater control of their treatment administration," she added.
Klygefa simultaneously blocks the C5 protein to limit neuromuscular damage in gMG and binds to serum albumin to extend its half-life. In the PREVAIL trial, it achieved a statistically significant improvement from baseline in gMG symptoms, measured using the MG-ADL scale, over 26 weeks.
Unlike Soliris and Ultomiris, which were developed for a broad range of complement-mediated diseases, AZ and Alexion have targeted Klygefa at the gMG category, in part to avoid cannibalising Ultomiris and oral Factor D inhibitor Voydeya (danicopan) in core indications like paroxysmal nocturnal haemoglobinuria (PNH) and haemolytic uraemic syndrome (HUS).
